TABLE 7.

Clinical response at the end of treatment and 7 days after the end of treatment in patients with febrile neutropenia

Efficacy outcomeNo. (%) of patients
Group 1 (200 mg q.i.d./ 400 mg b.i.d.)Group 2 (400 mg q.i.d./ 600 mg b.i.d.)Group 3 (800 mg b.i.d./ 800 mg q.d.)Total
Efficacy evaluableAll randomizedEfficacy evaluableAll randomizedEfficacy evaluableAll randomizedEfficacy evaluableAll randomized
End of treatment
    Total1923182116225366
    Success14 (74)14 (61)14 (78)14 (67)13 (81)14 (64)41 (77)42 (64)
    Failure5 (26)9 (39)4 (23)7 (33)3 (19)8 (36)12 (23)24 (36)
        Clinical failure5 (26)6 (26)3 (17)4 (19)2 (13)2 (9)10 (19)12 (18)
        Missing03 (13)1 (6)3 (14)1 (6)6 (27)2 (4)12 (18)
Posttreatment plus 7 daysa
    Total17171347
    Success13 (76)14 (82)11 (85)38 (81)
    Failure4 (24)3 (18)2 (15)9 (19)
        Clinical failure4 (24)2 (12)2 (15)8 (17)
        Missing01 (6)01 (2)
  • a Data for clinical efficacy 7 days after end of treatment were not collected for all randomized patients.